Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

医学 帕妥珠单抗 乳腺癌 曲妥珠单抗 多西紫杉醇 内科学 肿瘤科 来曲唑 三苯氧胺 卡铂 化疗 随机对照试验 临床终点 癌症 顺铂
作者
José Manuel Pérez-García,Géraldine Gebhart,Manuel Ruíz Borrego,Agostina Stradella,Begoña Bermejo,Peter Schmid,Frederik Marmé,Santiago Escrivá-de-Romaní,Lourdes Calvo,Nuria Ribelles,Noelia Martínez-Jáñez,Cinta Albacar,Aleix Prat,Florence Dalenc,Khaldoun Kerrou,Marco Colleoni,N. Afonso,Serena Di Cosimo,Miguel Sampayo-Cordero,Andrea Malfettone
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (6): 858-871 被引量:117
标识
DOI:10.1016/s1470-2045(21)00122-4
摘要

Several de-escalation approaches are under investigation in patients with HER2-positive, early-stage breast cancer. We assessed early metabolic responses to neoadjuvant trastuzumab and pertuzumab using 18F-fluorodeoxyglucose (18F-FDG)-PET (18F-FDG-PET) and the possibility of chemotherapy de-escalation using a pathological response-adapted strategy.We did a multicentre, randomised, open-label, non-comparative, phase 2 trial in 45 hospitals in Spain, France, Belgium, Germany, the UK, Italy, and Portugal. Eligible participants were women aged 18 years or older with centrally confirmed, HER2-positive, stage I-IIIA, invasive, operable breast cancer (≥1·5 cm tumour size) with at least one breast lesion evaluable by 18F-FDG-PET, an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left ventricular ejection fraction of at least 55%. We randomly assigned participants (1:4), via an interactive response system using central block randomisation with block sizes of five, stratified by hormone receptor status, to either docetaxel (75 mg/m2 intravenous), carboplatin (area under the concentration-time curve 6 mg/mL per min intravenous), trastuzumab (subcutaneous 600 mg fixed dose), and pertuzumab (intravenous 840 mg loading dose, 420 mg maintenance doses; group A); or trastuzumab and pertuzumab (group B). Hormone receptor-positive patients allocated to group B were additionally given letrozole if postmenopausal (2·5 mg/day orally) or tamoxifen if premenopausal (20 mg/day orally). Centrally reviewed 18F-FDG-PET scans were done before randomisation and after two treatment cycles. Patients assigned to group A completed six cycles of treatment (every 3 weeks) regardless of 18F-FDG-PET results. All patients assigned to group B initially received two cycles of trastuzumab and pertuzumab. 18F-FDG-PET responders in group B continued this treatment for six further cycles; 18F-FDG-PET non-responders in this group were switched to six cycles of docetaxel, carboplatin, trastuzumab, and pertuzumab. Surgery was done 2-6 weeks after the last dose of study treatment. Adjuvant treatment was selected according to the neoadjuvant treatment administered, pathological response, hormone receptor status, and clinical stage at diagnosis. The coprimary endpoints were the proportion of 18F-FDG-PET responders in group B with a pathological complete response in the breast and axilla (ypT0/is ypN0) as determined by a local pathologist after surgery after eight cycles of treatment, and 3-year invasive disease-free survival of patients in group B, both assessed by intention to treat. The definitive assessment of pathological complete response was done at this primary analysis; follow-up to assess invasive disease-free survival is continuing, hence these data are not included in this Article. Safety was assessed in all participants who received at least one dose of study drug. Health-related quality-of-life was assessed with EORTC QLQ-C30 and QLQ-BR23 questionnaires at baseline, after two cycles of treatment, and before surgery. This trial is registered with EudraCT (2016-002676-27) and ClinicalTrials.gov (NCT03161353), and is ongoing.Between June 26, 2017, and April 24, 2019, we randomly assigned 71 patients to group A and 285 to group B. Median follow-up was 5·7 months (IQR 5·3-6·0). 227 (80%) of 285 patients in group B were 18F-FDG-PET responders, of whom 86 (37·9%, 95% CI 31·6-44·5; p<0·0001 compared with the historical rate) of 227 had a pathological complete response. The most common haematological grade 3-4 adverse events were anaemia (six [9%] of 68 patients in group A vs four [1%] of 283 patients in group B), neutropenia (16 [24%] vs ten [4%]), and febrile neutropenia (14 [21%] vs 11 [4%]). Serious adverse events occurred in 20 (29%) of 68 patients in group A versus 13 (5%) of 283 patients in group B. No deaths were reported during neoadjuvant treatment. Global health status declined by at least 10% in 65·0% (95% CI 46·5-72·4) and 35·5% (29·7-41·7) of patients in groups A and B, respectively INTERPRETATION: 18F-FDG-PET identified patients with HER2-positive, early-stage breast cancer who were likely to benefit from chemotherapy-free dual HER2 blockade with trastuzumab and pertuzumab, and a reduced impact on global health status. Depending on the forthcoming results for the 3-year invasive disease-free survival endpoint, this strategy might be a valid approach to select patients not requiring chemotherapy.F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
学好久完成签到 ,获得积分10
1秒前
a24017完成签到,获得积分10
4秒前
YG完成签到,获得积分10
5秒前
yue完成签到,获得积分10
9秒前
淼队完成签到,获得积分10
10秒前
10秒前
落叶解三秋完成签到,获得积分10
11秒前
Crystal完成签到 ,获得积分10
14秒前
小小酥完成签到,获得积分10
14秒前
等待蚂蚁完成签到 ,获得积分10
15秒前
zgt01发布了新的文献求助10
15秒前
心心完成签到 ,获得积分10
16秒前
123完成签到,获得积分10
17秒前
温超完成签到,获得积分10
17秒前
量子星尘发布了新的文献求助10
17秒前
18秒前
19秒前
Menta1y完成签到,获得积分10
19秒前
czzlancer完成签到,获得积分10
20秒前
汶溢完成签到,获得积分10
20秒前
xsss完成签到,获得积分10
21秒前
TAN完成签到,获得积分10
21秒前
通通通发布了新的文献求助10
22秒前
liudw完成签到,获得积分10
22秒前
丹丹子完成签到 ,获得积分10
23秒前
时光完成签到,获得积分10
23秒前
24秒前
充电宝应助vsvsgo采纳,获得10
26秒前
123完成签到 ,获得积分10
28秒前
Ammr完成签到 ,获得积分10
28秒前
无限的依波完成签到,获得积分10
28秒前
姽婳wy发布了新的文献求助10
29秒前
lemon完成签到,获得积分10
29秒前
传奇3应助duckspy采纳,获得30
30秒前
陈木木完成签到,获得积分10
31秒前
可可西里完成签到,获得积分10
32秒前
奋斗蜗牛完成签到,获得积分10
32秒前
CipherSage应助眼睛大的擎苍采纳,获得10
32秒前
打打应助小小酥采纳,获得10
33秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022